Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

furosemide

- PMLiVE

Teva backs UK’s dementia drive with $21m investment

Pharma company will support National Institute for Health Research

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

- PMLiVE

EMA to restrict use of domperidone and diacerein

Regulator's pharmacovigilance advisors also want insomnia drug zolpidem's labelling tightened up

- PMLiVE

Pfizer recalls depression drug in US

Wrong medicine found in bottle of Effexor XR

- PMLiVE

Compulsory evaluation in France

French authorities will expect robust health economic cases to be made for some drugs

Teva Pharma logo

Teva launches first inhaled antipsychotic in US

Adasuve available for the treatment of agitation associated with schizophrenia or bipolar disorder

- PMLiVE

Gliptins don’t cause pancreatic cancer say FDA and EMA

Regulators back safety of diabetes medicine class

EU flag

Pharma wants review of EMA pharmacovigilance fees

EFPIA among associations to call for ‘balanced and transparent’ funding

- PMLiVE

FDA expands efforts to test quality of generics

Monitoring programme to ensure drug copies are equivalent to branded medicines

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

EMA and FDA create pharmacovigilance ‘cluster’

Monthly meetings to discuss key issues in medicines safety

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links